Tapewire

Nasdaq · USD

NBIX

NEUROCRINE BIOSCIENCES INC

Export transactions ↓
Tapewire entity
2655
SEC CIK
0000914475
Parsed reports
676

Last 12 months

Inside the activity.

0 purchase rows · 40 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202504
Dec 202504
Jan 202602
Feb 202600
Mar 202600
Apr 202600
May 202606
Jun 2026015
Jul 202606
Aug 202600
Sep 202603
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
February 13, 2024 Filed Feb 15, 2024 22:51 UTC
ROBERTS EIRYChief Medical Officer
GrantRestricted Stock Unit · Derivative 4,483 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000076 · wk-form4_1708037478.xml · derivative · entry 3

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,483

Underlying: Common Stock · 4,483 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:51 UTC
ROBERTS EIRYChief Medical Officer
GrantStock Option · Derivative 22,529 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000076 · wk-form4_1708037478.xml · derivative · entry 2

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,529

Underlying: Common Stock · 22,529 shares

Expires 2034-02-13

F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:51 UTC
ROBERTS EIRYChief Medical Officer
SaleCommon Stock 1,114 $132.96 $148,121.78
Disclosure

SEC source: 0000914475-24-000076 · wk-form4_1708037478.xml · nonDerivative · entry 1

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,716

F1 · kind: Sale of 1,114 shares of common stock issued upon vesting of 2,113 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (999) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: 18,336 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:48 UTC
Onyia JudeChief Scientific Officer
GrantRestricted Stock Unit · Derivative 10,760 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000075 · wk-form4_1708037291.xml · derivative · entry 3

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,760

Underlying: Common Stock · 10,760 shares

Expires not disclosed

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:48 UTC
Onyia JudeChief Scientific Officer
GrantStock Option · Derivative 54,069 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000075 · wk-form4_1708037291.xml · derivative · entry 2

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,069

Underlying: Common Stock · 54,069 shares

Expires 2034-02-13

F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:48 UTC
Onyia JudeChief Scientific Officer
SaleCommon Stock 1,432 $132.94 $190,371.08
Disclosure

SEC source: 0000914475-24-000075 · wk-form4_1708037291.xml · nonDerivative · entry 1

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,128

F1 · kind: Sale of 1,432 shares of common stock issued upon vesting of 2,717 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,285) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $133.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:45 UTC
Lippoldt DarinChief Legal Officer
GrantRestricted Stock Unit · Derivative 8,070 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000074 · wk-form4_1708037139.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,070

Underlying: Common Stock · 8,070 shares

Expires not disclosed

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:45 UTC
Lippoldt DarinChief Legal Officer
GrantStock Option · Derivative 40,552 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000074 · wk-form4_1708037139.xml · derivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,552

Underlying: Common Stock · 40,552 shares

Expires 2034-02-13

F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:45 UTC
Lippoldt DarinChief Legal Officer
SaleCommon Stock 1,098 $132.99 $146,028.40
Disclosure

SEC source: 0000914475-24-000074 · wk-form4_1708037139.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,740

F1 · kind: Sale of 1,098 shares of common stock issued upon vesting of 2,083 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (985) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:43 UTC
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
GrantRestricted Stock Unit · Derivative 22,415 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000073 · wk-form4_1708037005.xml · derivative · entry 3

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,415

Underlying: Common Stock · 22,415 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:43 UTC
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
GrantStock Option · Derivative 112,644 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000073 · wk-form4_1708037005.xml · derivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,644

Underlying: Common Stock · 112,644 shares

Expires 2034-02-13

F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:43 UTC
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
SaleCommon Stock 2,832 $133.02 $376,700.46
Disclosure

SEC source: 0000914475-24-000073 · wk-form4_1708037005.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 514,596

F1 · kind: Sale of 2,832 shares of common stock issued upon vesting of 5,376 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,544) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.98 to $134.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:40 UTC
Gano KyleChief Business Development Off
GrantRestricted Stock Unit · Derivative 8,966 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000072 · wk-form4_1708036809.xml · derivative · entry 3

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,966

Underlying: Common Stock · 8,966 shares

Expires not disclosed

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:40 UTC
Gano KyleChief Business Development Off
GrantStock Option · Derivative 45,058 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000072 · wk-form4_1708036809.xml · derivative · entry 2

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,058

Underlying: Common Stock · 45,058 shares

Expires 2034-02-13

F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:40 UTC
Gano KyleChief Business Development Off
SaleCommon Stock 1,352 $132.89 $179,673.63
Disclosure

SEC source: 0000914475-24-000072 · wk-form4_1708036809.xml · nonDerivative · entry 1

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,166

F1 · kind: Sale of 1,352 shares of common stock issued upon vesting of 2,566 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,214) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.98 to $133.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:38 UTC
Delaet IngridChief Regulatory Officer
GrantRestricted Stock Unit · Derivative 5,604 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000071 · wk-form4_1708036687.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,604

Underlying: Common Stock · 5,604 shares

Expires not disclosed

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:38 UTC
Delaet IngridChief Regulatory Officer
GrantStock Option · Derivative 28,161 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000071 · wk-form4_1708036687.xml · derivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,161

Underlying: Common Stock · 28,161 shares

Expires 2034-02-13

F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:38 UTC
Delaet IngridChief Regulatory Officer
SaleCommon Stock 716 $133.03 $95,252.77
Disclosure

SEC source: 0000914475-24-000071 · wk-form4_1708036687.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,507

F1 · kind: Sale of 716 shares of common stock issued upon vesting of 1,358 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (642) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.52. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:35 UTC
Cooke JulieChief Human Resources Officer
GrantRestricted Stock Unit · Derivative 5,604 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000070 · wk-form4_1708036535.xml · derivative · entry 3

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,604

Underlying: Common Stock · 5,604 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:35 UTC
Cooke JulieChief Human Resources Officer
GrantStock Option · Derivative 28,161 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000070 · wk-form4_1708036535.xml · derivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,161

Underlying: Common Stock · 28,161 shares

Expires 2034-02-13

F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:35 UTC
Cooke JulieChief Human Resources Officer
SaleCommon Stock 796 $133.04 $105,902.15
Disclosure

SEC source: 0000914475-24-000070 · wk-form4_1708036535.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,976

F1 · kind: Sale of 796 shares of common stock issued upon vesting of 1,509 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (713) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:33 UTC
Boyer David W.Chief Corp. Affairs Officer
GrantRestricted Stock Unit · Derivative 6,165 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000069 · wk-form4_1708036355.xml · derivative · entry 4

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,165

Underlying: Common Stock · 6,165 shares

Expires not disclosed

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:33 UTC
Boyer David W.Chief Corp. Affairs Officer
GrantStock Option · Derivative 30,977 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000069 · wk-form4_1708036355.xml · derivative · entry 3

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,977

Underlying: Common Stock · 30,977 shares

Expires 2034-02-13

F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:33 UTC
Boyer David W.Chief Corp. Affairs Officer
SaleCommon Stock 856 $133.05 $113,889.43
Disclosure

SEC source: 0000914475-24-000069 · wk-form4_1708036355.xml · nonDerivative · entry 2

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,895

F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:33 UTC
Boyer David W.Chief Corp. Affairs Officer
SaleCommon Stock 955 $133.10 $127,106.30
Disclosure

SEC source: 0000914475-24-000069 · wk-form4_1708036355.xml · nonDerivative · entry 1

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,751

F1 · kind: Sale of 955 shares of common stock issued upon vesting of 1,811 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (856) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:29 UTC
BENEVICH ERICChief Commercial Officer
GrantRestricted Stock Unit · Derivative 7,846 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000068 · wk-form4_1708036181.xml · derivative · entry 3

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,846

Underlying: Common Stock · 7,846 shares

Expires not disclosed

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:29 UTC
BENEVICH ERICChief Commercial Officer
GrantStock Option · Derivative 39,426 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000068 · wk-form4_1708036181.xml · derivative · entry 2

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,426

Underlying: Common Stock · 39,426 shares

Expires 2034-02-13

F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:29 UTC
BENEVICH ERICChief Commercial Officer
SaleCommon Stock 1,098 $133.01 $146,050.36
Disclosure

SEC source: 0000914475-24-000068 · wk-form4_1708036181.xml · nonDerivative · entry 1

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,616

F1 · kind: Sale of 1,098 shares of common stock issued upon vesting of 2,083 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (985) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:27 UTC
ABERNETHY MATTChief Financial Officer
GrantRestricted Stock Unit · Derivative 8,966 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000067 · wk-form4_1708036041.xml · derivative · entry 3

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,966

Underlying: Common Stock · 8,966 shares

Expires not disclosed

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:27 UTC
ABERNETHY MATTChief Financial Officer
GrantStock Option · Derivative 45,058 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000067 · wk-form4_1708036041.xml · derivative · entry 2

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,058

Underlying: Common Stock · 45,058 shares

Expires 2034-02-13

F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:27 UTC
ABERNETHY MATTChief Financial Officer
SaleCommon Stock 1,352 $132.85 $179,611.58
Disclosure

SEC source: 0000914475-24-000067 · wk-form4_1708036041.xml · nonDerivative · entry 1

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,528

F1 · kind: Sale of 1,352 shares of common stock issued upon vesting of 2,566 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,214) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $133.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:46 UTC
Boyer David W.Chief Corp. Affairs Officer
SaleCommon Stock 628 $136.78 $85,897.84
Disclosure

SEC source: 0000914475-24-000051 · wk-form4_1707439596.xml · nonDerivative · entry 4

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,895

F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:46 UTC
Boyer David W.Chief Corp. Affairs Officer
SaleCommon Stock 700 $134.19 $93,932.30
Disclosure

SEC source: 0000914475-24-000051 · wk-form4_1707439596.xml · nonDerivative · entry 3

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,523

F3 · kind: Sale of 700 shares of common stock issued upon vesting of 1,329 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (629) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:35 UTC
Cooke JulieChief Human Resources Officer
SaleCommon Stock 629 $136.78 $86,034.62
Disclosure

SEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 4

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,263

F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F6 · balance_after: 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:35 UTC
Cooke JulieChief Human Resources Officer
SaleCommon Stock 700 $134.23 $93,960.86
Disclosure

SEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 3

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,892

F4 · kind: Sale of 700 shares of common stock issued upon vesting of 1,329 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (629) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:28 UTC
ROBERTS EIRYChief Medical Officer
SaleCommon Stock 980 $134.21 $131,521.98
Disclosure

SEC source: 0000914475-24-000049 · wk-form4_1707438524.xml · nonDerivative · entry 2

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,717

F3 · kind: Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5 · balance_after: 18,336 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:25 UTC
Lippoldt DarinChief Legal Officer
SaleCommon Stock 911 $134.24 $122,288.90
Disclosure

SEC source: 0000914475-24-000048 · wk-form4_1707438316.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,755

F3 · kind: Sale of 911 shares of common stock issued upon vesting of 1,727 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (816) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:21 UTC
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
SaleCommon Stock 2,274 $134.15 $305,052.32
Disclosure

SEC source: 0000914475-24-000046 · wk-form4_1707438093.xml · nonDerivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 506,962

F3 · kind: Sale of 2,274 shares of common stock issued upon vesting of 4,317 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,043) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.75 to $136.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:17 UTC
Gano KyleChief Business Development Off
SaleCommon Stock 980 $134.20 $131,519.14
Disclosure

SEC source: 0000914475-24-000045 · wk-form4_1707437835.xml · nonDerivative · entry 2

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 133,952

F3 · kind: Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:15 UTC
BENEVICH ERICChief Commercial Officer
SaleCommon Stock 980 $134.19 $131,508.65
Disclosure

SEC source: 0000914475-24-000044 · wk-form4_1707437696.xml · nonDerivative · entry 2

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,631

F3 · kind: Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:12 UTC
ABERNETHY MATTChief Financial Officer
SaleCommon Stock 980 $134.21 $131,529.23
Disclosure

SEC source: 0000914475-24-000043 · wk-form4_1707437515.xml · nonDerivative · entry 2

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,314

F3 · kind: Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8 , 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:46 UTC
Boyer David W.Chief Corp. Affairs Officer
SaleCommon Stock 216 $141.96 $30,663.36
Disclosure

SEC source: 0000914475-24-000051 · wk-form4_1707439596.xml · nonDerivative · entry 2

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,894

F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:46 UTC
Boyer David W.Chief Corp. Affairs Officer
SaleCommon Stock 240 $141.96 $34,070.40
Disclosure

SEC source: 0000914475-24-000051 · wk-form4_1707439596.xml · nonDerivative · entry 1

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,110

F1 · kind: Sale of 240 shares of common stock issued upon vesting of 456 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (216) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:35 UTC
Cooke JulieChief Human Resources Officer
SaleCommon Stock 575 $141.96 $81,627.00
Disclosure

SEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,263

F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:35 UTC
Cooke JulieChief Human Resources Officer
SaleCommon Stock 640 $142.17 $90,989.76
Disclosure

SEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,838

F1 · kind: Sale of 640 shares of common stock issued upon vesting of 1,215 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (575) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.05 to $143.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:28 UTC
ROBERTS EIRYChief Medical Officer
SaleCommon Stock 1,121 $142.24 $159,446.11
Disclosure

SEC source: 0000914475-24-000049 · wk-form4_1707438524.xml · nonDerivative · entry 1

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,837

F1 · kind: Sale of 1,121 shares of common stock issued upon vesting of 2,126 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,005) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.40 to $143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:25 UTC
Lippoldt DarinChief Legal Officer
SaleCommon Stock 1,041 $142.17 $147,995.12
Disclosure

SEC source: 0000914475-24-000048 · wk-form4_1707438316.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,939

F1 · kind: Sale of 1,041 shares of common stock issued upon vesting of 1,975 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (934) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:21 UTC
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
SaleCommon Stock 3,040 $142.18 $432,218.38
Disclosure

SEC source: 0000914475-24-000046 · wk-form4_1707438093.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 504,919

F1 · kind: Sale of 3,040 shares of common stock issued upon vesting of 5,771 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,731) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:17 UTC
Gano KyleChief Business Development Off
SaleCommon Stock 1,600 $142.20 $227,522.08
Disclosure

SEC source: 0000914475-24-000045 · wk-form4_1707437835.xml · nonDerivative · entry 1

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 133,072

F1 · kind: Sale of 1,600 shares of common stock issued upon vesting of 3,037 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,437) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.07 to $142.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:15 UTC
BENEVICH ERICChief Commercial Officer
SaleCommon Stock 1,280 $142.12 $181,910.02
Disclosure

SEC source: 0000914475-24-000044 · wk-form4_1707437696.xml · nonDerivative · entry 1

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,751

F1 · kind: Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $142.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.